Repligen Corporation (NASDAQ:RGEN) Receives $174.58 Consensus PT from Brokerages

Repligen Corporation (NASDAQ:RGEN) has been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $174.5833.

A number of research firms have weighed in on RGEN. KeyCorp restated an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. Weiss Ratings lowered Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, March 3rd. Wells Fargo & Company decreased their price objective on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. Barclays dropped their price objective on Repligen from $200.00 to $175.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Finally, Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Rockefeller Capital Management L.P. raised its stake in shares of Repligen by 201.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 579 shares of the biotechnology company’s stock worth $95,000 after acquiring an additional 387 shares in the last quarter. MidFirst Bank acquired a new stake in Repligen in the fourth quarter valued at approximately $299,000. Pacer Advisors Inc. grew its holdings in Repligen by 2.5% in the fourth quarter. Pacer Advisors Inc. now owns 10,469 shares of the biotechnology company’s stock worth $1,715,000 after purchasing an additional 256 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in Repligen by 12.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 646,122 shares of the biotechnology company’s stock worth $105,874,000 after purchasing an additional 74,044 shares during the last quarter. Finally, Compound Planning Inc. acquired a new position in shares of Repligen during the fourth quarter worth $204,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Trading Up 3.6%

NASDAQ:RGEN opened at $119.27 on Friday. Repligen has a one year low of $102.96 and a one year high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.12 and a current ratio of 8.37. The firm has a market cap of $6.72 billion, a P/E ratio of 140.32, a P/E/G ratio of 2.25 and a beta of 1.14. The firm has a 50-day simple moving average of $143.28 and a 200-day simple moving average of $146.98.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $197.91 million for the quarter, compared to the consensus estimate of $192.23 million. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The company’s quarterly revenue was up 18.1% on a year-over-year basis. During the same period last year, the firm earned $0.44 earnings per share. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities analysts anticipate that Repligen will post 1.72 EPS for the current fiscal year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.